humanTNFand several N-terminal deletion mutants of TNFwas attempted using the excretion vector pEAP8. The TNF mutant with two N-terminal amino acids deleted (Nzl 2-TNF) was efficiently excreted into the culture mediumby E. coli carrying the plasmid pEXTNF3. In this clone, the signal peptide was correctly processed during the excretion. The E. coli-excreted Nzl2-TNFhad higher antitumor activity than wild-type TNF or N/I2-TNF produced intracellularly by E. coli.
Tumor necrosis factor-a (TNF) was identified by Carswell et al.1] in the serum of mice infected with Bacillus Calmett-Guerin and subsequently treated with endotoxin. Since TNF has been found to cause hemorrhagic necrosis of Meth A sarcoma and other transplantable tumors without destroying normal tissues, this substance appears highly promising as an anticancer agent.
The gene for human TNF has now been cloned and expressed in Escherichia coli, 2~6) making large quantities of pure TNFavailable for clinical trials in patients with advanced cancer. However, the TNFwhich is produced within E. coli cells has failed to provide satisfactory anticancer effects when administered alone, particularly by systemic administration. This is largely due to the fact that the dose required for the anticancer effect is very close to the toxic level, and therefore adequate quantities cannot be safely administered.
On the other hand, before the availability of recombinant TNF, basic experi-3241 ments had been done using natural TNF produced by stimulation of animals other than man. In those systems, no toxicity ofTNFwas observed, and a wide gap between the effective and toxic doses was documented.7) Thus, TNF produced within E. coli cells and natural TNF display widely different activities, and one reason for this maybe differences in the tertiary structures of the two substances.7'8) Wehave bred a strain of E. coli producing extracellularly the Fc region protein of human immunoglobulin Gt by weak activation of the kit gene, which is present in a dormant state in the plasmid pMB9.9) This Fc protein, when produced intracellularly by E. coli, assumes a monomeric form.10'1^However, extracellularly-excreted Fc protein is dimeric, joined by disulfied bonds at the hinge region,9) and resembles natural Fc protein with respect to its tertiary structure and functional aspects. 
Materials and Methods
Bacterial strains and plasmids. The hosts used in these studies were E. coli C600r"m" (ATCC 33525) and E. coli HB101 (ATCC 33694).
The vector used for intracellular expression was pAA41,n) while pEAP813) was used for extracellular expression.
Chemical synthesis of DNA and cloning techniques. Oligonucleotides were synthesized using a Model 380A DNAsynthesizer (Applied Biosystems). Synthesized oligonucleotides were purified by polyacrylamide gel electrophoresis (PAGE).
The cloning techniques used were as described in the manual by Maniatis et al.14) Analysis of TNF gene expression. E. coli with extracellular expression plasmids was cultivated at 37°C
for at least 24hr in LB medium (0.5% yeast extract, 1% tryptone, and 1 % sodium chloride; pH 7.2). Fractionation of the extracellular, periplasmic, and cytoplasmic fractions of the culture material was done by the method of Kato et al.13 ) Each fraction was concentrated by the acetone precipitation method. E. coli with intracellular expression plasmids was inoculated into M9medium14) containing 1% casamino acids, 1 % glucose, and 30/ig/ml ampicillin. The cells were cultured at 37°C until the optical density at 600 nm reached 0.7; then, after adding 50/zg/ml of indoleacrylic acid, the culture was continued overnight at 37°C. After the end of this incubation period, the bacteria were pelleted by centrifugation, the cells were disrupted by sonication, and the cell debris was removed by centrifuging to form a lysate, which corresponded to the cytoplasmic fraction of The amino acid composition of the purified TNFwas analyzed with a PICO-TAGamino acid analysis system (Waters), and the amino acid sequence of the N-terminus was identified with a Model 470A amino acid sequencer (Applied Biosystems).
Assessmentofantitumor activity. The in vitro antitumor activity of each sample containing E. co//-produced TNF was assayed by the method of Ruff and Gifford,18) using murine L929 cells (ATCC CCL-929). One unit (U) was defined as the quantity ofTNF required to kill 50% of a sample of 4 x 104 cells in the presence of actinomycin D in 18hr.
In vivo activity was assayed by the method of Carswell et al.1] In brief, 5 x 105 murine Meth A sarcoma cells19) were suspended in 50/il of RPMI1640 medium (Flow Laboratories) and subcutaneously transplanted to the lateral abdomen of BALB/c mice (male; 6-8 weeks of age) (Charles River). Seven to ten days after transplantation, when the tumor had grown to a diameter of 6-8mm, E. co/z-produced TNF was injected into the caudal vein, and gene, the previously reported DNAsequence of human TNFcDNA2)was regarded as the fundamental structure, and suitable restriction enzymecleavage sites were established to facilitate subsequent cloning procedures and gene modifications. Also, a translation initiation codon (ATG) and tendem stop codon (TGA-TAG) were added upstream to the 5'-end and downstream to the 3'-end, respectively, so that the resulting reading frames coincided. The DNAsequence of the TNF gene designed in this manner is shown in Fig. 1 Figure 3 shows the methods for the construction of these plasmids. E. coli HB101 strain cells transformed with the extracellular expression plasmids or the vector plasmid pEAP8 were cultivated, and the extracellular, periplasmic, and cytoplasmic fractions were collected. Immunoblotting analysis of each fraction was done (Fig. 4) .
The extracellular fraction of E coli HB101 [pEXTNF3] showed a band believed to represent mature mutant TNF, while the cytoplasmic fraction showed a band corresponding to the precursor of the mutant TNF. Oligonucleotides Used (B). The plasmis pTNF401A was digested with Aval (for pEXTNF4 and pEXTNF3) or HapII (for pEXTNF2), and Hindlll to obtain a TNF-gene-containing fragment. Oligonucleotides were kinated, annealed, and used as linkers. The DNAfragments containing the TNFgene and synthetic oligonucleotides were ligated and cloned into the Hindlll site ofpEAP8 to construct pEXTNF4,pEXTNF3,and pEXTNF2.Moreover, pEAP8 was digested with Hindlll and filled in with Klenow fragment to obtain a linear pEAP8fragment with flush ends. The TNF-gene-containing Aval-Hindlll fragment cleaved from pTNF401Awas also filled in with Klenow fragment and then ligated with the linear pEAP8fragment to construct pEXTNFl. Ex, Ex promoter; kil, kil gene; P, penicillinase promoter region; S, penicillinase signal peptide coding region; Ptrp, tryptophan operon promoter region.
In this clone, the excretion efficiency was estimated about 85%of total TNFmutant protein by measuring the density of the appropriate product band on a nitrocellulose immunoblotting analysis. Table I shows the transformed with pEXTNF3, pEXTNF4, and distribution of in vitro antitumor activity in the pEXTNFl, demonstrating that excretion of fractions. In vitro antitumor activity was shown TNFwith the various N-terminal deletions did by the culture supernatants from those occur in the E. coli carrying these plasmids.
The results shown in Fig. 4 and The cytoplasmic TNFwas purified from the lysate of E. coli C600r"m"[pTNF401A] by affinity chromatography using anti-human TNF monoclonal antibody. The relative molecular mass (Mr) of the cytoplasmic TNF as indicated by SDS-PAGE was approximately 17 kirodaltons (kDa) (data not shown), which agrees well with the Mr of 17,356 daltons inferred from the primary structure of the sequence of 157 amino acid residues. On the other hand, after gel filtration, a substance was eluted at the position corresponding to an Mr of about 30-35kDa, suggesting that the cytoplasmic TNF assumes an oligomeric form in solution. Also, investigation of the amino acid sequence in the vicinity of the N-terminus of the cytoplasmic TNFfound three species of TNF molecules; that is, one retaining the terminal methionine residue originating from the initiation codon, a second from which this methionine residue had been cleaved off, and a third lacking the two last residues at the N-terminus. The third molecular species is believed to arise from the action of proteases present in E. coli cells. The proportion of this species could be reduced by adding protease inhibitors during the purification process, but in any case, it was shown that the N-termini of the cytoplasmic TNFwere not uniform. The mutant TNFwas also purified by affinity chromatography from culture supernates of E. excreted by E. coli was H2N-Ser-Ser-Ser-ArgThr-Pro-SerAsp-. This showed that the signal peptide was properly cleaved during the process of excretion, and that mature protein in the form of NJ2-TNFwas extracellularly excreted as anticipated. The aminoacid composition of the mutant TNFexcreted by E. coli (hereinafter referred to as excreted NJ2-TNF)was mostly consistent with that calculated from the DNA sequence (data not shown). was put on each lane. Figure 5 shows the results of native-PAGE of cytoplasmic TNF and excreted NJ2-TNF. Cytoplasmic TNFhad a multiplicity of at least 4 to 5 bands, but the pattern for excreted NJ2-TNF consisted of nearly just a single band. Moreover, in isoelectric focusing (IEF), cytoplasmic TNFdisplayed several bands in the region of pH 5.4-6.5, while the band pattern of excreted NzJ2-TNF was almost entirely concentrated at the position corresponding to pH 5.7 (data not shown). This again demonstrated that cytoplasmic TNF is not uniform in composition, while excreted -N-d2-TNF has a nearly uniform composition, consisting almost entirely of NJ2-TNF.
Biological activities of recombinant TNFs
The in vitro antitumor activities of purified cytoplasmic TNF and excreted NJ2-TNF are shown in Table II . Excreted Nzl2-TNF had 2.4 times higher specific activity than cytoplasmic TNF.Furthermore, the intracellular expression plasmid pTNF428A encoding NJ2-TNF was derived from the plasmid pTNF401A using suitable synthetic oligonucleotides as described previously.21} Cytoplasmic Nzl2-TNF was purified from the lysate of E. coli C600r~m[ pTNF428A] and its in vitro antitumor activity was measured. The specific activity ofcytoplasmic Nzl2-TNF was only half as much as that of excreted NJ2-TNF, although cytoplasmic NJ2-TNF had 1.3 times higher specific activity than cytoplasmic TNF. TNF cannot be explained solely on the basis of deletion of the two N-terminal amino acids, and appears to be largely due to some optimization of the tertiary structure during the process of excretion. Further studies are under way to define the tertiary structure of excreted NzJ2-TNF by NMR and X-ray crystallography.
